moderate or severe hepatic impairment (Child-Pugh Class A, B or C); however safety and efficacy of a SOF-based regimen have not been established in patients with decompensated cirrhosis. SOF的药量调整没有为患者需要与温和,适度或者严厉肝损伤 (孩子Pugh类A, B或者C); 然而基于SOF的养生之道的安全...
Brockmoller J; Thomsen T; Wittstock M;.Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis ( Child - Pugh classes A, B, and C ) : characterization by dynamic liver function tests.Clin Pharmacol Ther.2005.529-551...
Hepatic impairment: Hepatic impairment: Generally, no dose adjustment is recommended when Fintepla is administered without concomitant stiripentol to patients with mild and moderate hepatic impairment (Child-Pugh Class A and B). In patients with sev...
aPatients with hepatic impairment (total bilirubin > ULN or Child-Pugh A, B and C) should be closely monitored during therapy with TARCEVA 有肝损伤(总胆红素> ULN或者孩子Pugh A、B和C的)病人在疗法期间与TARCEVA,应该严密被监测[translate]
目的 探讨肝硬化患者血清腺苷脱氨酶(ADA)活性,肝纤维化标志物透明质酸(HA)水平与Child-Pugh分级及其相关性.方法 采用连续监测法和放射免疫法(RIA)测定了108例肝硬化患者,40例对照组血清ADA活性和HA水平.结果 肝硬化Child-A,Child-B,Child-C级患者,血清ADA活性,HA水平均明显升高,差异显著(P<0.01),并随肝硬化...
Child-Pugh is a prognostic clinical score with limitations in reflecting the liver's metabolic capacity. Aims To demonstrate the need for better drug dosing approaches in hepatic impairment, summarise the current status, identify knowledge gaps related to drug kinetic parameters in hepatic impairment, ...
HepQuant DSI, SHUNT%, and hepatic reserve were more useful predictors of drug exposure than Child‐Pugh class for ampreloxetine and thus may better optimize dose recommendations in patients with liver disease. The simple‐to‐administer, oral‐only DuO version of the HepQuant test could ...
aIn a pharmacokinetic study in patients with moderate hepatic impairment (Child-Pugh B) associated with significant liver tumor burden, 10 out of 15 patients died on treatment or within 30 days of the last TARCEVA dose. 在一项约物动力学的研究中在病人有适度肝损伤(孩子Pugh B)与重大肝脏肿瘤负担...